Taro/TARO

$42.19

0%
-
1D1W1MYTD1YMAX

About Taro

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Ticker

TARO

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Uday Baldota

Employees

1,554

Headquarters

Haifa, Israel

Taro Metrics

BasicAdvanced
$1.59B
Market cap
34.74
P/E ratio
$1.22
EPS
0.60
Beta
-
Dividend rate
$1.59B
0.596
$45.76
$24.22
51.47K
3.602
3.028
30.443
2.14%
2.61%
2.59%
34.739
2.599
0.892
0.901
18.46
7.23%
-0.51%
-3.86%
-52.58%

What the Analysts think about Taro

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 1 analyst.
1.92% upside
High $43.00
Low $43.00
$42.19
Current price
$43.00
Average price target

Taro Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
12.85% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$157.1M
6.01%
Net income
$20.2M
137.65%
Profit margin
12.85%
124.26%

Taro Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 80%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$0.18
$0.27
$0.23
$0.54
-
Expected
$0.23
$0.31
$0.18
$0.30
$0.31
Surprise
-21.74%
-12.9%
27.78%
80%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Taro stock?

Taro (TARO) has a market cap of $1.59B as of April 19, 2024.

What is the P/E ratio for Taro stock?

The price to earnings (P/E) ratio for Taro (TARO) stock is 34.74 as of April 19, 2024.

Does Taro stock pay dividends?

No, Taro (TARO) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next Taro dividend payment date?

Taro (TARO) stock does not pay dividends to its shareholders.

What is the beta indicator for Taro?

Taro (TARO) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Taro stock price target?

The target price for Taro (TARO) stock is $43, which is 1.92% above the current price of $42.19. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Taro stock

Buy or sell Taro stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing